1
|
Zhao H, Lu Y, Li S, Qin J, Xu M, Ye H, Yang Z, Rao J, Chen G, Su F, Hu Z, Xu L. Voriconazole plus flucytosine is not superior to amphotericin B deoxycholate plus flucytosine as an induction regimen for cryptococcal meningitis treatment. Mycoses 2024; 67:e13674. [PMID: 37986630 DOI: 10.1111/myc.13674] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2023] [Revised: 10/21/2023] [Accepted: 11/01/2023] [Indexed: 11/22/2023]
Abstract
BACKGROUND The efficacy and side effects of voriconazole plus 5-flucytosine (Vori + 5-FC) versus amphotericin B deoxycholate plus 5-flucytosine (AmBd + 5-FC) as an induction treatment for cryptococcal meningitis are unknown. METHODS Forty-seven patients treated with Vori + 5-FC and 92 patients treated with AmBd + 5-FC were included in the current study after propensity score matching (PSM) at a ratio of 1:2. Two-week laboratory test results and 90-day mortality were compared between the two groups. RESULTS After 2 weeks of induction treatment, the CSF Cryptococcus sterile culture rate was 57.1% in the Vori + 5-FC group and 76.5% in the AmBd + 5-FC group (p = .026). No difference was found in the normalization of CSF indicators (glucose, total protein, intracranial pressure and India ink sterile rate) between the two groups. Both the Vori + 5FC regimen and AmBd + 5-FC regimen obviously decreased haemoglobin concentrations, platelet counts and serum potassium levels (all p ≤ .010). Notably, the Vori + 5FC regimen did not influence serum creatinine levels (p = .263), while AmBd + 5FC increased serum creatinine levels (p = .019) after 2-week induction treatment. The Vori + 5-FC group and AmBd + 5-FC group had similar 90-day cumulative survival rates (89.9% vs. 87.8%, p = .926). CONCLUSION The Vori + 5-FC regimen was associated with low 2-week CSF sterile culture and was not superior to AmBd + 5-FC as induction therapy in terms of the 90-day cumulative survival rate of CM patients.
Collapse
Affiliation(s)
- Handan Zhao
- National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | - Yanqiu Lu
- Chongqing Public Health Medical Center, Southwest University Public Health Hospital, Chongqing, China
| | - Shan Li
- Department of Infectious Diseases, The Ninth Hospital of Nanchang, Nanchang, China
| | - Jiangying Qin
- National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | - Miaomiao Xu
- Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China
| | - Hui Ye
- Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, China
| | - Zongxing Yang
- Xixi Hospital of Hangzhou, College of Medicine, Zhejiang University, Hangzhou, China
| | - Jianfeng Rao
- Department of Infectious Diseases, The Ninth Hospital of Nanchang, Nanchang, China
| | - Guochun Chen
- Department of Infectious Diseases, The Third Peoples' Hospital of Changzhou, Changzhou, China
| | - Feifei Su
- Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, China
| | - Zhiliang Hu
- Department of Infectious Disease, The Second Hospital of Nanjing, Nanjing University of Chinese Medicine, Nanjing, China
| | - Lijun Xu
- National Clinical Research Center for Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- The State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| |
Collapse
|
2
|
Chen X, Chen F, Liang C, He G, Chen H, Wu Y, Chen Y, Shuai J, Yang Y, Dai C, Cao L, Wang X, Cai E, Wang J, Wu M, Zeng L, Zhu J, Hai D, Pan W, Pan S, Zhang C, Quan S, Su F. MRI advances in the imaging diagnosis of tuberculous meningitis: opportunities and innovations. Front Microbiol 2023; 14:1308149. [PMID: 38149270 PMCID: PMC10750405 DOI: 10.3389/fmicb.2023.1308149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Accepted: 11/14/2023] [Indexed: 12/28/2023] Open
Abstract
Tuberculous meningitis (TBM) is not only one of the most fatal forms of tuberculosis, but also a major public health concern worldwide, presenting grave clinical challenges due to its nonspecific symptoms and the urgent need for timely intervention. The severity and the rapid progression of TBM underscore the necessity of early and accurate diagnosis to prevent irreversible neurological deficits and reduce mortality rates. Traditional diagnostic methods, reliant primarily on clinical findings and cerebrospinal fluid analysis, often falter in delivering timely and conclusive results. Moreover, such methods struggle to distinguish TBM from other forms of neuroinfections, making it critical to seek advanced diagnostic solutions. Against this backdrop, magnetic resonance imaging (MRI) has emerged as an indispensable modality in diagnostics, owing to its unique advantages. This review provides an overview of the advancements in MRI technology, specifically emphasizing its crucial applications in the early detection and identification of complex pathological changes in TBM. The integration of artificial intelligence (AI) has further enhanced the transformative impact of MRI on TBM diagnostic imaging. When these cutting-edge technologies synergize with deep learning algorithms, they substantially improve diagnostic precision and efficiency. Currently, the field of TBM imaging diagnosis is undergoing a phase of technological amalgamation. The melding of MRI and AI technologies unquestionably signals new opportunities in this specialized area.
Collapse
Affiliation(s)
- Xingyu Chen
- Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, China
- The First School of Medicine, Wenzhou Medical University, Wenzhou, China
| | - Fanxuan Chen
- School of Biomedical Engineering, School of Ophthalmology and Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, China
| | - Chenglong Liang
- The First School of Medicine, Wenzhou Medical University, Wenzhou, China
| | - Guoqiang He
- Postgraduate Training Base Alliance of Wenzhou Medical University, Wenzhou, China
- Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, China
| | - Hao Chen
- The First School of Medicine, Wenzhou Medical University, Wenzhou, China
| | - Yanchan Wu
- School of Electrical and Information Engineering, Quzhou University, Quzhou, China
| | - Yinda Chen
- School of Electrical and Information Engineering, Quzhou University, Quzhou, China
| | - Jincen Shuai
- Baskin Engineering, University of California, Santa Cruz, CA, United States
| | - Yilei Yang
- The First School of Medicine, Wenzhou Medical University, Wenzhou, China
| | | | - Luhuan Cao
- Wenzhou Medical University, Wenzhou, China
| | - Xian Wang
- Wenzhou Medical University, Wenzhou, China
| | - Enna Cai
- Wenzhou Medical University, Wenzhou, China
| | | | | | - Li Zeng
- Wenzhou Medical University, Wenzhou, China
| | | | - Darong Hai
- Wenzhou Medical University, Wenzhou, China
| | - Wangzheng Pan
- Renji College of Wenzhou Medical University, Wenzhou, China
| | - Shuo Pan
- The First School of Medicine, Wenzhou Medical University, Wenzhou, China
| | - Chengxi Zhang
- School of Materials Science and Engineering, Shandong Jianzhu University, Jinan, China
| | - Shichao Quan
- Department of Big Data in Health Science, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
- Key Laboratory of Intelligent Treatment and Life Support for Critical Diseases of Zhejiang Province, Wenzhou, China
- Zhejiang Engineering Research Center for Hospital Emergency and Process Digitization, Wenzhou, China
| | - Feifei Su
- Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, China
- Wenzhou Key Laboratory of Diagnosis and Treatment of Emerging and Recurrent Infectious Diseases, Wenzhou, China
- Department of Infectious Diseases, Wenzhou Sixth People’s Hospital, Wenzhou, China
| |
Collapse
|
3
|
Miao X, Ye H, Cui X, Guo X, Su F. Resveratrol attenuates efavirenz-induced hepatic steatosis and hypercholesterolemia in mice by inhibiting pregnane X receptor activation and decreasing inflammation. Nutr Res 2023; 119:119-131. [PMID: 37826994 DOI: 10.1016/j.nutres.2023.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2023] [Revised: 09/14/2023] [Accepted: 09/14/2023] [Indexed: 10/14/2023]
Abstract
Efavirenz (EFV), a widely prescribed antiviral medication, has been implicated in dyslipidemia and can activate the pregnane X receptor (PXR), leading to hepatic steatosis and hypercholesterolemia in mice. Resveratrol (RES) can ameliorate hepatic steatosis and functions as a partial PXR agonist, capable of mitigating PXR expression induced by other PXR agonists. Therefore, we hypothesized that RES could attenuate EFV-induced hepatic steatosis and hypercholesterolemia by downregulating PXR expression and suppressing inflammatory cytokine production. Here, we conducted an in vivo study involving 6-week-old male mice, which were divided into 4 groups for a 7-day intervention: control (carrier solution), EFV (80 mg/kg), RES (50 mg/kg), and RES + EFV groups. Serum and hepatic tissue samples were collected to assess cholesterol and triglyceride concentrations. Hepatic lipid accumulation was evaluated through hematoxylin-eosin and oil red O staining. Polymerase chain reaction and western blot were performed to quantify hepatic inflammatory factors, lipogenic gene, and PXR expression. Our results indicated that hepatic lipid droplet accumulation was reduced in the RES + EFV group compared with the EFV group. Similarly, the expressions of hepatic inflammatory factors were attenuated in the RES + EFV group relative to the EFV group. Furthermore, RES counteracted the upregulation of hepatic lipid-metabolizing enzymes induced by EFV at both the transcriptional and protein levels. Importantly, PXR expression was downregulated in the RES + EFV group compared with the EFV group. Conclusively, our findings suggest that RES effectively mitigates EFV-induced hepatic steatosis and hypercholesterolemia by inhibiting PXR activation and decreasing inflammation.
Collapse
Affiliation(s)
- Xingguo Miao
- Department of Infectious Diseases, Wenzhou Central Hospital, Zhejiang, 325000, China; Department of Infectious Diseases, the Sixth People's Hospital of Wenzhou, Zhejiang, 325000, China; Institute of Translational Medicine, Shanghai University, Shanghai, 200444, China
| | - Hui Ye
- Department of Infectious Diseases, Wenzhou Central Hospital, Zhejiang, 325000, China; Department of Infectious Diseases, the Sixth People's Hospital of Wenzhou, Zhejiang, 325000, China
| | - Xiaoya Cui
- Department of Infectious Diseases, Wenzhou Central Hospital, Zhejiang, 325000, China; Department of Infectious Diseases, the Sixth People's Hospital of Wenzhou, Zhejiang, 325000, China
| | - Xiuxiu Guo
- Department of Infectious Diseases, Wenzhou Central Hospital, Zhejiang, 325000, China; Department of Infectious Diseases, the Sixth People's Hospital of Wenzhou, Zhejiang, 325000, China
| | - Feifei Su
- Department of Infectious Diseases, Wenzhou Central Hospital, Zhejiang, 325000, China; Department of Infectious Diseases, the Sixth People's Hospital of Wenzhou, Zhejiang, 325000, China.
| |
Collapse
|
4
|
André F, Su F, Solovieff N, Hortobagyi G, Chia S, Neven P, Bardia A, Tripathy D, Lu YS, Lteif A, Taran T, Babbar N, Slamon D, Arteaga CL. Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Ann Oncol 2023; 34:1003-1014. [PMID: 37673211 DOI: 10.1016/j.annonc.2023.08.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2022] [Revised: 08/04/2023] [Accepted: 08/28/2023] [Indexed: 09/08/2023] Open
Abstract
BACKGROUND The phase III MONALEESA trials tested the efficacy and safety of the cyclin-dependent kinase (CDK)4/6 inhibitor ribociclib with different endocrine therapy partners as first- or second-line treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). Using the largest pooled biomarker dataset of the CDK4/6 inhibitor ribociclib in ABC to date, we identified potential biomarkers of response to ribociclib. PATIENTS AND METHODS Baseline circulating tumour DNA from patients in the MONALEESA trials was assessed using next-generation sequencing. An analysis of correlation between gene alteration status and progression-free survival (PFS) was carried out to identify potential biomarkers of response to ribociclib. RESULTS Multiple frequently altered genes were identified. Alterations in ERBB2, FAT3, FRS2, MDM2, SFRP1, and ZNF217 were associated with a greater PFS benefit with ribociclib versus placebo. Patients with high tumour mutational burden (TMB) and with ANO1, CDKN2A/2B/2C, and RB1 alterations exhibited decreased sensitivity to ribociclib versus placebo. CONCLUSIONS Although exploratory, these results provide insight into alterations associated with the improved response to ribociclib treatment and may inform treatment sequencing in patients with actionable alterations following progression on CDK4/6 inhibitors. Validation of potential biomarkers identified here and development of prospective trials testing their clinical utility are warranted. CLINICALTRIALS GOV IDENTIFIERS NCT01958021, NCT02422615, NCT02278120.
Collapse
Affiliation(s)
- F André
- Department of Medical Oncology and INSERM U981, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France.
| | - F Su
- Novartis Pharmaceuticals, East Hanover
| | - N Solovieff
- Novartis Institutes for BioMedical Research, Cambridge
| | - G Hortobagyi
- The University of Texas MD Anderson Cancer Center, Houston, USA
| | - S Chia
- British Columbia Cancer Agency, Vancouver, Canada
| | - P Neven
- Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium
| | - A Bardia
- Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA
| | - D Tripathy
- The University of Texas MD Anderson Cancer Center, Houston, USA
| | - Y-S Lu
- National Taiwan University Hospital, Taipei, Taiwan
| | - A Lteif
- Novartis Pharmaceuticals, East Hanover
| | - T Taran
- Novartis Pharma AG, Basel, Switzerland
| | - N Babbar
- Novartis Pharmaceuticals, East Hanover
| | - D Slamon
- David Geffen School of Medicine at UCLA, Los Angeles
| | - C L Arteaga
- UT Southwestern Simmons Comprehensive Cancer Center, Dallas, USA
| |
Collapse
|
5
|
Shi Y, Zhang C, Pan S, Chen Y, Miao X, He G, Wu Y, Ye H, Weng C, Zhang H, Zhou W, Yang X, Liang C, Chen D, Hong L, Su F. The diagnosis of tuberculous meningitis: advancements in new technologies and machine learning algorithms. Front Microbiol 2023; 14:1290746. [PMID: 37942080 PMCID: PMC10628659 DOI: 10.3389/fmicb.2023.1290746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Accepted: 10/09/2023] [Indexed: 11/10/2023] Open
Abstract
Tuberculous meningitis (TBM) poses a diagnostic challenge, particularly impacting vulnerable populations such as infants and those with untreated HIV. Given the diagnostic intricacies of TBM, there's a pressing need for rapid and reliable diagnostic tools. This review scrutinizes the efficacy of up-and-coming technologies like machine learning in transforming TBM diagnostics and management. Advanced diagnostic technologies like targeted gene sequencing, real-time polymerase chain reaction (RT-PCR), miRNA assays, and metagenomic next-generation sequencing (mNGS) offer promising avenues for early TBM detection. The capabilities of these technologies are further augmented when paired with mass spectrometry, metabolomics, and proteomics, enriching the pool of disease-specific biomarkers. Machine learning algorithms, adept at sifting through voluminous datasets like medical imaging, genomic profiles, and patient histories, are increasingly revealing nuanced disease pathways, thereby elevating diagnostic accuracy and guiding treatment strategies. While these burgeoning technologies offer hope for more precise TBM diagnosis, hurdles remain in terms of their clinical implementation. Future endeavors should zero in on the validation of these tools through prospective studies, critically evaluating their limitations, and outlining protocols for seamless incorporation into established healthcare frameworks. Through this review, we aim to present an exhaustive snapshot of emerging diagnostic modalities in TBM, the current standing of machine learning in meningitis diagnostics, and the challenges and future prospects of converging these domains.
Collapse
Affiliation(s)
- Yi Shi
- Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, China
- The First School of Medicine, Wenzhou Medical University, Wenzhou, China
| | - Chengxi Zhang
- School of Materials Science and Engineering, Shandong Jianzhu University, Jinan, China
| | - Shuo Pan
- The First School of Medicine, Wenzhou Medical University, Wenzhou, China
| | - Yi Chen
- The First School of Medicine, Wenzhou Medical University, Wenzhou, China
| | - Xingguo Miao
- Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, China
- Department of Infectious Diseases, Wenzhou Sixth People’s Hospital, Wenzhou, China
- Wenzhou Key Laboratory of Diagnosis and Treatment of Emerging and Recurrent Infectious Diseases, Wenzhou, China
| | - Guoqiang He
- Postgraduate Training Base Alliance of Wenzhou Medical University, Wenzhou, China
- Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou, China
| | - Yanchan Wu
- School of Electrical and Information Engineering, Quzhou University, Quzhou, China
| | - Hui Ye
- Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, China
- Department of Infectious Diseases, Wenzhou Sixth People’s Hospital, Wenzhou, China
- Wenzhou Key Laboratory of Diagnosis and Treatment of Emerging and Recurrent Infectious Diseases, Wenzhou, China
| | - Chujun Weng
- The Fourth Affiliated Hospital Zhejiang University School of Medicine, Yiwu, China
| | - Huanhuan Zhang
- School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China
| | - Wenya Zhou
- School and Hospital of Stomatology, Wenzhou Medical University, Wenzhou, China
| | - Xiaojie Yang
- Wenzhou Medical University Renji College, Wenzhou, China
| | - Chenglong Liang
- The First School of Medicine, Wenzhou Medical University, Wenzhou, China
| | - Dong Chen
- Wenzhou Key Laboratory of Diagnosis and Treatment of Emerging and Recurrent Infectious Diseases, Wenzhou, China
- Wenzhou Central Blood Station, Wenzhou, China
| | - Liang Hong
- Department of Infectious Diseases, The Third Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
| | - Feifei Su
- Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, China
- Department of Infectious Diseases, Wenzhou Sixth People’s Hospital, Wenzhou, China
- Wenzhou Key Laboratory of Diagnosis and Treatment of Emerging and Recurrent Infectious Diseases, Wenzhou, China
| |
Collapse
|
6
|
Zhu J, Wang A, Miao X, Ye H, Pan S, Zhang C, Qian Q, Su F. Harnessing gradient gelatin nanocomposite hydrogels: a progressive approach to tackling antibacterial biofilms. RSC Adv 2023; 13:30453-30461. [PMID: 37854485 PMCID: PMC10580021 DOI: 10.1039/d3ra06034a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Accepted: 09/30/2023] [Indexed: 10/20/2023] Open
Abstract
Infectious wounds pose significant challenges due to their susceptibility to bacterial infections, hindering tissue repair. This study introduces gradient gelatin nanocomposite hydrogels for wound healing and antibacterial biofilm management. These hydrogels, synthesized via UV light polymerization, incorporate copper-doped polydopamine nanoparticles (PDA-Cu) and GelMA (gelatin methacrylate). The hydrogels have a unique structure with a porous upper layer and a denser lower layer, ensuring superior swelling (over than 600%) and effective contact with bacterial biofilms. In vitro experiments demonstrate their remarkable antibacterial properties, inhibiting S. aureus and E. coli biofilms by over 45% and 53%, respectively. This antibacterial action is attributed to the regulation of reactive oxygen species (ROS) production, an alternative mechanism to bacterial cell wall disruption. Moreover, the hydrogels exhibit high biocompatibility with mammalian cells, making them suitable for medical applications. In vivo evaluation in a rat wound infection model shows that the gradient hydrogel treatment effectively controls bacterial biofilm infections and accelerates wound healing. The treated wounds have smaller infected areas and reduced bacterial colony counts. Histological analysis reveals reduced inflammation and enhanced granulation tissue formation in treated wounds, highlighting the therapeutic potential of these gradient nanocomposite hydrogels. In summary, gradient gelatin nanocomposite hydrogels offer promising multifunctional capabilities for wound healing and biofilm-related infections, paving the way for innovative medical dressings with enhanced antibacterial properties and biocompatibility.
Collapse
Affiliation(s)
- Jiawei Zhu
- Infectious Disease Department, Wenzhou Central Hospital Wenzhou 325099 Zhejiang People's Republic of China
| | - Anli Wang
- Infectious Disease Department, Wenzhou Central Hospital Wenzhou 325099 Zhejiang People's Republic of China
| | - Xingguo Miao
- Infectious Disease Department, Wenzhou Central Hospital Wenzhou 325099 Zhejiang People's Republic of China
| | - Hui Ye
- Infectious Disease Department, Wenzhou Central Hospital Wenzhou 325099 Zhejiang People's Republic of China
| | - Shuo Pan
- Wenzhou Medical University Wenzhou 325000 Zhejiang People's Republic of China
| | - Chengxi Zhang
- School of Materials Science and Engineering, Shandong Jianzhu University Jinan 250101 China
| | - Qiuping Qian
- Infectious Disease Department, Wenzhou Central Hospital Wenzhou 325099 Zhejiang People's Republic of China
- Zhejiang Engineering Research Center for Tissue Repair Materials, Wenzhou Institute, University of Chinese Academy of Sciences Wenzhou 325000 Zhejiang People's Republic of China
- Departamento de Química Física, Biomedical Research Center (CINBIO), Universidade de Vigo 36310 Vigo Spain
| | - Feifei Su
- Infectious Disease Department, Wenzhou Central Hospital Wenzhou 325099 Zhejiang People's Republic of China
| |
Collapse
|
7
|
Su F, Meng XX, Su CZ, Zhang JL. A case of drug-induced myopathy in alcoholic cirrhosis caused by voriconazole. Eur Rev Med Pharmacol Sci 2023; 27:3833-3836. [PMID: 37203807 DOI: 10.26355/eurrev_202305_32288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/20/2023]
Abstract
BACKGROUND Voriconazole is a new generation of broad-spectrum antifungal agents commonly used in the treatment of invasive aspergillus infections. CASE REPORT We reported a rare case of myopathy induced by voriconazole, which showed severe muscle pain and significantly elevated myocardial enzymes. Enzymes eventually achieved good efficacy by switching voriconazole to micafungin and the use of L-carnitine. CONCLUSIONS This reminded us it was necessary to be vigilant for rare adverse reactions of voriconazole in the population with liver dysfunction, the elderly population, and people with multiple underlying diseases in clinical practice. During medication of voriconazole, close attention should be paid to the occurrence of adverse reactions to avoid life-threatening complications.
Collapse
Affiliation(s)
- F Su
- Department of Hepatology, Hebei Traditional Chinese Medicine Hospital, Shijiazhuang, China.
| | | | | | | |
Collapse
|
8
|
Wang F, Zhang YT, Su F, Huang CP, Luo L. [Determination of methylmercury in urine by direct mercury analyzer]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2023; 41:304-306. [PMID: 37248187 DOI: 10.3760/cma.j.cn121094-20211110-00556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Objective: To develop asolvent extraction-direct mercury analyzer method for determination of methylmercury in urine. Methods: After the urinehydrolyzesd by hydrobromic acid, methylmercury was extracted by tolueneand reverse-extracted from L-cysteine solution, it was then detectedbydirect mercuryanalyzer. Results: The linear range was 0.2-50.0 μg/L, and the related coefficient was 0.9999. The relative standard deviations (RSD) within the group were 5.04%-6.64%, and the RSD between the group were 5.65%-8.11 %. The average recovery efficiencies were 85.4%-95.5%. The detection limitation was 0.0482 μg/L and the quantification concentrations was 0.1607 μg/L. Conclusion: The method, which has low detection limit, high sensitivity, easy to operate, is stability for the determination of methylmercury in urine.
Collapse
Affiliation(s)
- F Wang
- Department of Chemical Laboratory, Longhua District Center for Disease Control and Prevention, Shenzhen 518109, China
| | - Y T Zhang
- Department of Occupational and Environmental Health, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China
| | - F Su
- Department of Occupational and Environmental Health, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China
| | - C P Huang
- Department of Chemical Laboratory, Longhua District Center for Disease Control and Prevention, Shenzhen 518109, China
| | - L Luo
- Department of Chemical Laboratory, Longhua District Center for Disease Control and Prevention, Shenzhen 518109, China
| |
Collapse
|
9
|
Keable R, Hu S, Pfundstein G, Kozlova I, Su F, Du X, Yang H, Gunnersen J, Schachner M, Leshchyns'ka I, Sytnyk V. The BACE1-generated C-terminal fragment of the neural cell adhesion molecule 2 (NCAM2) promotes BACE1 targeting to Rab11-positive endosomes. Cell Mol Life Sci 2022; 79:555. [PMID: 36251052 PMCID: PMC9576659 DOI: 10.1007/s00018-022-04575-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 09/16/2022] [Accepted: 09/27/2022] [Indexed: 11/08/2022]
Abstract
Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), also known as β-secretase, is an aspartic protease. The sorting of this enzyme into Rab11-positive recycling endosomes regulates the BACE1-mediated cleavage of its substrates, however, the mechanisms underlying this targeting remain poorly understood. The neural cell adhesion molecule 2 (NCAM2) is a substrate of BACE1. We show that BACE1 cleaves NCAM2 in cultured hippocampal neurons and NCAM2-transfected CHO cells. The C-terminal fragment of NCAM2 that comprises the intracellular domain and a small portion of NCAM2’s extracellular domain, associates with BACE1. This association is not affected in cells with inhibited endocytosis, indicating that the interaction of NCAM2 and BACE1 precedes the targeting of BACE1 from the cell surface to endosomes. In neurons and CHO cells, this fragment and BACE1 co-localize in Rab11-positive endosomes. Overexpression of full-length NCAM2 or a recombinant NCAM2 fragment containing the transmembrane and intracellular domains but lacking the extracellular domain leads to an increase in BACE1 levels in these organelles. In NCAM2-deficient neurons, the levels of BACE1 are increased at the cell surface and reduced in intracellular organelles. These effects are correlated with increased levels of the soluble extracellular domain of BACE1 in the brains of NCAM2-deficient mice, suggesting increased shedding of BACE1 from the cell surface. Of note, shedding of the extracellular domain of Sez6, a protein cleaved exclusively by BACE1, is reduced in NCAM2-deficient animals. These results indicate that the BACE1-generated fragment of NCAM2 regulates BACE1 activity by promoting the targeting of BACE1 to Rab11-positive endosomes.
Collapse
Affiliation(s)
- Ryan Keable
- School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia
| | - Shangfeng Hu
- School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia
| | - Grant Pfundstein
- School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia
| | - Irina Kozlova
- School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia
| | - Feifei Su
- School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia
| | - Ximing Du
- School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia
| | - Hongyuan Yang
- School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia
| | - Jenny Gunnersen
- Department of Anatomy and Physiology, School of Biomedical Sciences, Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, VIC, 3010, Australia
| | - Melitta Schachner
- Department of Cell Biology and Neuroscience, Keck Center for Collaborative Neuroscience, Rutgers University, Piscataway, NJ, 08554, USA
| | - Iryna Leshchyns'ka
- School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia
| | - Vladimir Sytnyk
- School of Biotechnology and Biomolecular Sciences, The University of New South Wales, Sydney, NSW, 2052, Australia.
| |
Collapse
|
10
|
Cui X, Su F, Ye H, Jiang Y, Guo X. Disseminated talaromycosis complicated by recurrent gastrointestinal bleeding and hemorrhagic shock: a case report. BMC Infect Dis 2022; 22:238. [PMID: 35264100 PMCID: PMC8905750 DOI: 10.1186/s12879-022-07230-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2021] [Accepted: 03/01/2022] [Indexed: 01/12/2023] Open
Abstract
Background Gastrointestinal involvement is not uncommon in patients with disseminated talaromycosis, but successful management of massive gastrointestinal bleeding and hemorrhagic shock secondary to talaromycosis is rarely reported. Clinical management strategies for these patients have not been well documented. Case presentation Here, we reported a case of disseminated talaromycosis with recurrent gastrointestinal bleeding and hemorrhagic shock who was successfully alleviated solely with medical treatment. Conclusions Early diagnosis and treatment for Talaromyces marneffei, intravenous fluid resuscitation, hemostatic therapy and blood transfusion are all essential for talaromycosis complicated with gastrointestinal bleeding and hemorrhagic shock. It is also necessary to warn about the possibility of bleeding induced or aggravated by endoscopic biopsy trauma.
Collapse
Affiliation(s)
- Xiaoya Cui
- Department of Infectious Diseases, Wenzhou Center Hospital, Wenzhou, 325000, Zhejiang Province, China.
| | - Feifei Su
- Department of Infectious Diseases, Wenzhou Center Hospital, Wenzhou, 325000, Zhejiang Province, China
| | - Hui Ye
- Department of Infectious Diseases, Wenzhou Center Hospital, Wenzhou, 325000, Zhejiang Province, China
| | - Yi Jiang
- Department of Pathology, Wenzhou Center Hospital, Wenzhou, 325000, Zhejiang Province, China
| | - Xiuxiu Guo
- Department of Infectious Diseases, Wenzhou Center Hospital, Wenzhou, 325000, Zhejiang Province, China
| |
Collapse
|
11
|
Kraus R, Weil C, Su F, Burt L, Mendez J. Incidence and Extent of Disease Progression on MRI Between Surgery and Initiation of Radiotherapy in Glioblastoma Patients. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
12
|
Su F, Ma R, Zhang N, Li YY, Hei Y, Xu X, Yang XJ. [A case report of orbital epithelioid hemangioendothelioma]. Zhonghua Yan Ke Za Zhi 2021; 57:696-698. [PMID: 34865408 DOI: 10.3760/cma.j.cn112142-20201203-00794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
A 70-year-old male patient, who had a right upper eyelid tumor excision 4 years ago, complained of eyelid swelling and ptosis for 3 months. Orbital CT and MRI showed an orbital cystic lesion with hemorrhage in the right eye. The tumor was resected under general anesthesia. The pathological diagnosis was epithelioid hemangioendothelioma. (Chin J Ophthalmol, 2021, 57:696-698).
Collapse
Affiliation(s)
- F Su
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - R Ma
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - N Zhang
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - Y Y Li
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - Y Hei
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - X Xu
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| | - X J Yang
- Department of Ophthalmology, the Third Medical Center of Chinese PLA General Hospital, Beijing 100039, China
| |
Collapse
|
13
|
Carey L, Pierga JY, Kümmel S, Jerusalem G, De Laurentiis M, Miller M, Li Z, Kaper M, Su F, Loi S. 275P A phase II study of LAG525 in combination with spartalizumab (PDR001), PDR001 and carboplatin (Carbo), or Carbo, as first- or second-line therapy in patients (Pts) with advanced (Adv) triple-negative breast cancer (tnbc). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
14
|
Yeang C, Su F, Witztum J, Tsimikas S. Novel method for quantification of lipoprotein(a)-cholesterol: Implications for improving accuracy of LDL-C measurements. Atherosclerosis 2021. [DOI: 10.1016/j.atherosclerosis.2021.06.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
15
|
Han D, Yuan RX, Su F. LINC00511 can promote the proliferation, migration and invasion of esophageal cancer cells through regulating microRNA-150-5p. Eur Rev Med Pharmacol Sci 2021; 24:2462-2469. [PMID: 32196597 DOI: 10.26355/eurrev_202003_20514] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The aim of this study was to investigate the potential role of LINC00511 in esophageal cancer (ECa), and to explore its underlying mechanism through in vitro cell experiments. PATIENTS AND METHODS LINC00511 expression in ECa was analyzed by GEPIA database and verified by real-time fluorescence quantitative polymerase chain reaction (qPCR). The bioinformatics website was used to analyze the miRNAs that can bind to LINC00511, and the regulatory relationship between them was verified through Luciferase assay, qPCR as well as Western blotting analysis. Then, the impacts of LINC00511 and microRNA-150-5p on the proliferation or invasiveness of ECa cell lines Kyse30 and ECA109 were investigated by cell counting kit-8 (CCK-8) test and transwell experiment, respectively. Meanwhile, cell cycle and apoptosis were detected by flow cytometry. RESULTS Analysis results of the GEPIA database revealed that LINC00511 had a significant high expression in ECa tissue samples in comparison with normal control ones, which is consistent with qPCR results. Meanwhile, a significant negative correlation was found between LINC00511 and microRNA-150-5p. In brief, LINC00511 was able to bind to microRNA-150-5p and inhibited its expression. Besides, overexpression of LINC00511 enhanced ECa cell proliferation and migration, accelerated cell cycle, and suppressed cell apoptosis, while transfection with microRNA-150-5p mimics caused the opposite effects. CONCLUSIONS This study shows for the first time that LINC00511 modulates the progression of ECa by binding to microRNA-150-5p.
Collapse
Affiliation(s)
- D Han
- Department of Digestive, Shanxian Central Hospital of Shandong Province, Heze, China.
| | | | | |
Collapse
|
16
|
Miao X, Ye H, Yang S, Su F. Concurrence of Talaromycosis and Kaposi Sarcoma in an HIV-Infected Patient: A Case Report. Curr HIV Res 2021; 19:195-198. [PMID: 33153422 DOI: 10.2174/1570162x18999201105161137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2020] [Revised: 10/02/2020] [Accepted: 10/10/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Concurrence of talaromycosis, an infection caused by the opportunistic fungal pathogen Talaromyces marneffei and Kaposi sarcoma, a common vascular tumor, is a rare but severe medical condition in patients infected with the human immunodeficiency virus (HIV). Despite poor outcomes, the clinical characteristics and management strategies for HIV-infected patients with comorbid Kaposi sarcoma and talaromycosis have not been well documented. CASE PRESENTATION A 33-year-old HIV-positive male patient presented to the Department of Infectious Diseases at Wenzhou Central Hospital with cough, sputum expectoration, hemoptysis, rashes on the feet and violaceous plaques in the oral cavity. Chest computed tomography (CT) showed bilateral nodules, patchy shadows and lymphadenectasis. Skin biopsy and histopathological examination indicated Kaposi sarcoma. T. marneffei was isolated from blood cultures and suggested talaromycosis. The patient's overall conditions significantly improved following initiation of combination antiretroviral therapy (cART) and chemotherapy for Kaposi sarcoma and antifungal treatment for talaromycosis. CONCLUSION Severe medical conditions such as Kaposi sarcoma and talaromycosis may coexist in HIV-infected patients and pose an increased risk of mortality. Etiological diagnosis and treatment are the keys to the successful management of HIV-infected patients with these concurrent conditions.
Collapse
Affiliation(s)
- Xingguo Miao
- Department of Infectious Diseases, Wenzhou Central Hospital, Zhejiang, 32500, China
| | - Hui Ye
- Department of Infectious Diseases, Wenzhou Central Hospital, Zhejiang, 32500, China
| | - Shoufeng Yang
- Department of Infectious Diseases, Wenzhou Central Hospital, Zhejiang, 32500, China
| | - Feifei Su
- Department of Infectious Diseases, Wenzhou Central Hospital, Zhejiang, 32500, China
| |
Collapse
|
17
|
Su F, Shi M, Zhang J, Li Y, Tian J. Recombinant high‑mobility group box 1 induces cardiomyocyte hypertrophy by regulating the 14‑3‑3η, PI3K and nuclear factor of activated T cells signaling pathways. Mol Med Rep 2021; 23:214. [PMID: 33495819 PMCID: PMC7845624 DOI: 10.3892/mmr.2021.11853] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2019] [Accepted: 09/07/2020] [Indexed: 01/20/2023] Open
Abstract
High-mobility group box 1 (HMGB1) is released by necrotic cells and serves an important role in cardiovascular pathology. However, the effects of HMGB1 in cardiomyocyte hypertrophy remain unclear. Therefore, the aim of the present study was to investigate the potential role of HMGB1 in cardiomyocyte hypertrophy and the underlying mechanisms of its action. Neonatal mouse cardiomyocytes (NMCs) were co-cultured with recombinant HMGB1 (rHMGB1). Wortmannin was used to inhibit PI3K activity in cardiomyocytes. Subsequently, atrial natriuretic peptide (ANP), 14-3-3 and phosphorylated-Akt (p-Akt) protein levels were detected using western blot analysis. In addition, nuclear factor of activated T cells 3 (NFAT3) protein levels were measured by western blot analysis and observed in NMCs under a confocal microscope. The results revealed that rHMGB1 increased ANP and p-Akt, and decreased 14-3-3η protein levels. Furthermore, wortmannin abrogated the effects of rHMGB1 on ANP, 14-3-3η and p-Akt protein levels. In addition, rHMGB1 induced nuclear translocation of NFAT3, which was also inhibited by wortmannin pretreatment. The results of this study suggest that rHMGB1 induces cardiac hypertrophy by regulating the 14-3-3η/PI3K/Akt/NFAT3 signaling pathway.
Collapse
Affiliation(s)
- Feifei Su
- Department of Cardiology, Air Force Medical Center, People's Liberation Army, Beijing 100142, P.R. China
| | - Miaoqian Shi
- Department of Cardiology, The Seventh Medical Centre of The People's Liberation Army General Hospital, Beijing 100700, P.R. China
| | - Jian Zhang
- Department of Cardiology, Beijing Chest Hospital Heart Center, Capital Medical University, Beijing 101149, P.R. China
| | - Yan Li
- Department of Cardiology, Tangdu Hospital Affiliated to The Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
| | - Jianwei Tian
- Department of Cardiology, Air Force Medical Center, People's Liberation Army, Beijing 100142, P.R. China
| |
Collapse
|
18
|
Hu C, Zhou F, Zhu L, Su F, Zhou C. Effect of Ultrasound Images Based on Filtering Algorithm on the Diagnosis Efficiency of Cervical Lymph Node Tuberculosis. j med imaging hlth inform 2021. [DOI: 10.1166/jmihi.2021.3431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Objective: This paper uses filtering algorithms to explore and analyze the characteristics of cervical tuberculous lymph nodes and metastatic lymph nodes in ultrasound sonograms. Methods: 160 lymph nodes of 105 patients who obtained pathological results were retrospectively
analyzed in this paper, including 76 tuberculous lymph nodes and 84 metastatic lymph nodes. The following ultrasound findings of lymph nodes in the two groups were compared: L/S, border, lymphatic door, internal echo, calcification, necrosis and liquefaction, and their characteristics
were analyzed. Results: Both calcifications and liquid echoless areas were present in both groups. The internal calcifications of metastatic lymph nodes were mostly micro-calcifications, which were clustered, and the tuberculous lymph nodes were mostly scattered coarse calcifications.
The difference was statistically significant (P < 0.01). The liquefaction area in metastatic lymph nodes was mostly eccentric and the area ratio was less than 50%. The liquefaction area in tuberculous lymph nodes was mostly in the center and the area ratio was more than 50%. The
difference was statistically significant (P < 0 01). Conclusion: Ultrasound imaging features such as the size and distribution of calcification, and the location and area ratio of liquefaction zone are helpful to distinguish tuberculous lymph nodes from metastatic lymph nodes.
Collapse
|
19
|
Su F, Yang YY. Microbially induced carbonate precipitation via methanogenesis pathway by a microbial consortium enriched from activated anaerobic sludge. J Appl Microbiol 2020; 131:236-256. [PMID: 33187022 DOI: 10.1111/jam.14930] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2020] [Revised: 10/14/2020] [Accepted: 11/04/2020] [Indexed: 11/28/2022]
Abstract
AIMS Various applications of microbially induced carbonate precipitation (MICP) has been proposed. However, most studies use cultured pure strains to obtain MICP, ignoring advantages of microbial consortia. The aims of this study were to: (i) test the feasibility of a microbial consortium to produce MICP; (ii) identify functional micro-organisms and their relationship; (iii) explain the MICP mechanism; (iv) propose a way of applying the MICP technique to soil media. METHODS AND RESULTS Anaerobic sludge was used as the source of the microbial consortium. A laboratory anaerobic sequencing batch reactor and beaker were used to perform precipitation experiment. The microbial consortium produced MICP with an efficiency of 96·6%. XRD and SEM analysis showed that the precipitation composed of different-size calcite crystals. According to high-throughput 16S rRNA gene sequencing, the functional micro-organisms included acetogenic bacteria, acetate-oxidizing bacteria and archaea Methanosaeta and Methanobacterium beijingense. The methanogenesis acetate degradation provides dissolved inorganic carbon and increases pH for MICP. A series of reactions catalysed by many enzymes and cofactors of methanogens and acetate-oxidizers are involved in the acetate degradation. CONCLUSION This work demonstrates the feasibility of using the microbial consortium to achieve MICP from an experimental and theoretical perspective. SIGNIFICANCE AND IMPACT OF THE STUDY A method of applying the microbial-consortium MICP to soil media is proposed. It has the advantages of low cost, low environmental impact, treatment uniformity and less limitations from natural soils. This method could be used to improve mechanical properties, plug pores and fix harmful elements of soil media, etc.
Collapse
Affiliation(s)
- F Su
- School of Engineering and Technology, China University of Geosciences (Beijing), Beijing, P. R. China
| | - Y Y Yang
- School of Engineering and Technology, China University of Geosciences (Beijing), Beijing, P. R. China
| |
Collapse
|
20
|
Su F, Shi M, Zhang J, Zheng Q, Wang H, Li X, Chen J. MiR-223/NFAT5 signaling suppresses arterial smooth muscle cell proliferation and motility in vitro. Aging (Albany NY) 2020; 12:26188-26198. [PMID: 33373321 PMCID: PMC7803580 DOI: 10.18632/aging.202395] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2019] [Accepted: 10/31/2020] [Indexed: 01/11/2023]
Abstract
Aberrant proliferation and migration of vascular smooth muscle cells contributes to cardiovascular diseases (CVDs), including atherosclerosis. MicroRNA-223 (miR-223) protects against atherosclerotic CVDs. We investigated the contribution of miR-223 to platelet-derived growth factor-BB (PDGF-BB)-induced proliferation and migration of human aortic smooth muscle cells (HASMCs). We found that miR-223 was downregulated in PDGF-BB-treated HASMCs in a dose- and time-dependent manner, while nuclear factor of activated T cells 5 (NFAT5) was upregulated. Gain- and loss-of-function studies demonstrated that miR-223 treatment reduced PDGF-BB-induced HASMC proliferation and motility, whereas miR-223 inhibitor enhanced these processes. Moreover, NFAT5 was identified as a direct target of miR-223 in HASMC. The inhibitory effects of miR-223 on HASMC proliferation and migration were partly rescued by NFAT5 restoration. Overall, these findings suggest that miR-223 inhibits the PDGF-BB-induced proliferation and motility of HASMCs by targeting NFAT5 and that miR-223 and NFAT5 may be potential therapeutic targets for atherosclerosis.
Collapse
Affiliation(s)
- Feifei Su
- Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, Shaanxi, China.,Department of Cardiology, Air Force General Hospital, PLA, Beijing 100142, China
| | - Miaoqian Shi
- Department of Cardiology, PLA Army General Hospital, Beijing 100700, China
| | - Jian Zhang
- Department of Cardiology, Beijing Chest Hospital Heart Center, Capital Medical University, Beijing 101149, China
| | - Qiangsun Zheng
- Division of Cardiology, Second Affiliated Hospital of Xi’an Jiao Tong University, Xi'an 710004, Shaanxi, China
| | - Haichang Wang
- Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, Shaanxi, China
| | - Xue Li
- Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, Shaanxi, China
| | - Jianghong Chen
- Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi’an 710038, Shaanxi, China
| |
Collapse
|
21
|
Pan T, Chen D, Pan C, Kang Y, Liu J, Su F, Hong L, Li H, Zhao H, Lin Z, Wang X, Lin H, Du Q, Cai C, Chen Y. Characteristics of Liver Functions in Patients With COVID-19 and Construction of a Prognostic Evaluation Decision Model Based on Liver Functions. Infect Microbes Dis 2020; 2:151-159. [PMID: 38630095 PMCID: PMC7769056 DOI: 10.1097/im9.0000000000000039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 09/26/2020] [Accepted: 10/08/2020] [Indexed: 01/08/2023]
Abstract
A number of studies have suggested that coronavirus disease 2019 (COVID-19) can cause liver damage. However, clinical features and outcome of COVID-19 in patients with liver injury remain to be further investigated. In this study, the clinical data of 265 COVID-19 patients admitted to seven tertiary hospitals were collected. Based on a threshold for transaminase or total bilirubin levels at two times the normal upper limit, patients were divided into mild or moderate/severe liver injury groups. Among the 265 patients, 183 patients showed liver injury within 48 hours of admission. Aspartate aminotransferase levels were predominantly elevated in the liver injury group, but albumin levels were reduced. Moreover, fibrinogen and D-dimer were significantly increased. Furthermore, 68% of the patients with moderate/severe liver injury had one or more underlying diseases. Almost half of these patients developed acute respiratory distress syndrome (44%) and secondary infections (46%). These patients showed increased interleukin-6 and interleukin-10 levels and a decrease in PaO2 and the oxygenation index. In addition, levels of alanine aminotransferase, aspartate aminotransferase, and albumin were correlated with the oxygenation index, D-dimer and lymphocyte counts. Furthermore, a novel prognostic assessment model based on liver function was established, which accuracy reached 88% and was able to accurately assess the prognosis of COVID-19 patients.
Collapse
Affiliation(s)
- Tongtong Pan
- Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, The Key Laboratory of Diagnosis and Controlment for The Development of Chronic Liver Disease of Zhejiang Province, Wenzhou, Zhejiang, China
- Tongtong Pan and Dazhi Chen contributed equally to this work
| | - Dazhi Chen
- Department of Gastroenterology, Peking University First Hospital, Beijing, China
- Tongtong Pan and Dazhi Chen contributed equally to this work
| | - Chenwei Pan
- Department of Infectious Diseases, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Yi Kang
- Department of Infectious Diseases, Henan provincial people's hospital, Zhengzhou, Henan, China
| | - Junping Liu
- Department of Infectious Diseases, Henan provincial people's hospital, Zhengzhou, Henan, China
| | - Feifei Su
- Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, Zhejiang, China
| | - Liang Hong
- Department of Infectious Diseases, Rui’an People's Hospital, Wenzhou, Zhejiang, China
| | - Huili Li
- Department of Infectious Diseases, Cangnan People's Hospital, Wenzhou, Zhejiang, China
| | - Hui Zhao
- Department of Infectious Diseases, Yueqing Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China
| | - Zhuo Lin
- Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, The Key Laboratory of Diagnosis and Controlment for The Development of Chronic Liver Disease of Zhejiang Province, Wenzhou, Zhejiang, China
| | - Xiaodong Wang
- Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, The Key Laboratory of Diagnosis and Controlment for The Development of Chronic Liver Disease of Zhejiang Province, Wenzhou, Zhejiang, China
| | - Hongwei Lin
- Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, The Key Laboratory of Diagnosis and Controlment for The Development of Chronic Liver Disease of Zhejiang Province, Wenzhou, Zhejiang, China
| | - Qianjing Du
- Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, The Key Laboratory of Diagnosis and Controlment for The Development of Chronic Liver Disease of Zhejiang Province, Wenzhou, Zhejiang, China
| | - Chao Cai
- Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, The Key Laboratory of Diagnosis and Controlment for The Development of Chronic Liver Disease of Zhejiang Province, Wenzhou, Zhejiang, China
| | - Yongping Chen
- Department of Infectious Diseases, The First Affiliated Hospital of Wenzhou Medical University, The Key Laboratory of Diagnosis and Controlment for The Development of Chronic Liver Disease of Zhejiang Province, Wenzhou, Zhejiang, China
| |
Collapse
|
22
|
Su F, Li S, Shou J, Hong Q, Zhang ZX. [Giant spindle cell rhabdomyosarcoma of children in the thoracic cavity: a case report]. Zhonghua Zhong Liu Za Zhi 2020; 42:779-780. [PMID: 32988163 DOI: 10.3760/cma.j.cn112152-20190410-00230] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- F Su
- Department of Pathology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - S Li
- Department of Pathology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - J Shou
- Department of Pathology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Q Hong
- Department of Pathology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| | - Z X Zhang
- Department of Pathology, Guizhou Provincial People's Hospital, Guiyang 550002, China
| |
Collapse
|
23
|
Ren W, Yu Y, Tan Y, Chen Y, Liu J, He Z, Li A, Ma J, Lu N, Li C, Li X, Ou Q, Chen K, Hu Q, Ouyang J, Su F, Xie C, Song E, Yao H. 4MO Machine learning intratumoral and peritumoral magnetic resonance imaging radiomics for predicting disease-free survival in patients with early-stage breast cancer (RBC-01 Study). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
24
|
Hurvitz S, Chia S, Ciruelos E, Hu X, Im SA, Janni W, Jerusalem G, Lacouture M, O'Regan R, Rugo H, Yap Y, Ghaznawi F, Han Y, Su F, Chandarlapaty S. 352TiP EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human epidermal growth factor receptor-2–positive (HER2+) advanced breast cancer (ABC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.454] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
25
|
Yu Y, Tan Y, Hu Q, Ouyang J, Chen Y, Yang G, Li A, Lu N, He Z, Yang Y, Chen K, Ou Q, Zhang Y, Wu Z, Su F, Xie C, Song E, Yao H. 169MO Development and validation of a magnetic resonance imaging radiomics-based signature to predict axillary lymph node metastasis and disease-free survival in patients with breast cancer: A multicenter cohort study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
26
|
Xu L, Yu J, Zheng B, Su F, Yang Z, Guo Y, Tao R, Dai X, Huang Y, Shi J, Zhang Z, Chen Y, Zhu B. HIV Infection Does Not Increase 10-Week Mortality of Chinese Cryptococcal Meningitis Patients. AIDS Res Hum Retroviruses 2020; 36:734-741. [PMID: 32539429 DOI: 10.1089/aid.2020.0001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
The role of HIV infection in precipitating different clinical features in cryptococcal meningitis (CM) patients remains controversial. One hundred twelve CM patients living with HIV/AIDS (CM+HIV+ patients) and 112 CM patients living without HIV/AIDS (CM+HIV- patients) were enrolled after propensity score matching. Demographic characteristics, symptoms, routine blood tests, and biochemical and cerebrospinal fluid (CSF) profiles were compared between the two groups. Kaplan-Meier analysis and Cox proportional hazards model was used to assess 10-week mortality. CM+HIV+ patients frequently occurred in young (mean age 40.3 ± 10.5) and male (89.3%) populations who also experienced leukopenia, neutropenia, lymphocytopenia, thrombocytopenia, and hypoalbuminemia, less headaches (66.9%), and higher cryptococcemia (23.2%) (all p < .050); they also had higher glucose (2.6 ± 1.1 mmol/L), increased smear positivity (78.8%), and decreased white blood cells [8.0 (2.0-28.0) × 106/L] in initial CSF assay (all p < .050). The 10-week cumulative survival rate was 84.6% for CM+HIV+ patients and 88.5% for CM+HIV- patients (p = .345). Age <35.0 years (hazard ratio (HR) 3.0 (1.0-8.9), p = .046), intracranial pressure (ICP) >250.0 mmH2O (HR: 4.8 (1.1-21.6), p = .041), and treatment lacking amphotericin B [HR: 6.5 (1.9-21.4), p = .003] were independent risk factors for 10-week mortality in CM+HIV+ patients. There are significant clinical differences in CM patients living with or without HIV/AIDS. However, the 10-week survival rate was similar between the two groups. Younger population, high ICP, and treatment lacking amphotericin B were independent risk factors for 10-week mortality of Chinese CM+HIV+ patients.
Collapse
Affiliation(s)
- Lijun Xu
- National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the Department of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | - Jianhua Yu
- Department II of Infectious Diseases, Xixi Hospital of Hangzhou, Hangzhou, China
| | - Bin Zheng
- College of Medicine, Zhejiang University, Hangzhou, China
| | - Feifei Su
- Department of Infectious Diseases, Wenzhou Central Hospital, Wenzhou, China
| | - Zongxing Yang
- Department II of Infectious Diseases, Xixi Hospital of Hangzhou, Hangzhou, China
| | - Yongzheng Guo
- National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the Department of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | - Ran Tao
- National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the Department of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | - Xiahong Dai
- Department of Infectious Diseases, Shulan Hospital, Hangzhou, China
| | - Ying Huang
- National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the Department of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| | - Jinchuan Shi
- Department II of Infectious Diseases, Xixi Hospital of Hangzhou, Hangzhou, China
| | - Zhongdong Zhang
- Department II of Infectious Diseases, Xixi Hospital of Hangzhou, Hangzhou, China
| | - Yaokai Chen
- Department of Infectious Diseases, Chongqing Public Health Medical Center, Chongqing, China
| | - Biao Zhu
- National Clinical Research Center for Infectious Diseases, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the Department of Infectious Diseases, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China
| |
Collapse
|
27
|
Chen D, Hu C, Su F, Song Q, Wang Z. Exposure to SARS-CoV-2 in a high transmission setting increases the risk of severe COVID-19 compared with exposure to a low transmission setting? J Travel Med 2020; 27:5851814. [PMID: 32502262 PMCID: PMC7313864 DOI: 10.1093/jtm/taaa094] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2020] [Revised: 05/09/2020] [Accepted: 05/29/2020] [Indexed: 01/22/2023]
Affiliation(s)
- Dong Chen
- Department of Infectious Disease, The Ding Li Clinical College of Wenzhou Medical University and Sixth People's Hospital of Wenzhou, Wenzhou, Zhejiang, China
| | - Chenchan Hu
- Department of Infectious Disease, The Ding Li Clinical College of Wenzhou Medical University and Sixth People's Hospital of Wenzhou, Wenzhou, Zhejiang, China
| | - Feifei Su
- Department of Infectious Disease, The Ding Li Clinical College of Wenzhou Medical University and Sixth People's Hospital of Wenzhou, Wenzhou, Zhejiang, China
| | - Qifa Song
- Central Laboratory, Ningbo First Hospital, Ningbo, Zhejiang, China
| | - Zhen Wang
- Research Center of Blood Transfusion Medicine, Ministry of Education Key Laboratory of Laboratory Medicine, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China
| |
Collapse
|
28
|
Shao T, Tong Y, Lu S, Jeyarajan AJ, Su F, Dai J, Shi J, Huang J, Hu C, Wu L, Dai X, Cheng Z, Yan J, Huang P, Tian Y, Li S, Chung RT, Chen D. γ-Glutamyltransferase Elevations Are Frequent in Patients With COVID-19: A Clinical Epidemiologic Study. Hepatol Commun 2020; 4:1744-1750. [PMID: 32838106 PMCID: PMC7404935 DOI: 10.1002/hep4.1576] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Revised: 06/15/2020] [Accepted: 06/30/2020] [Indexed: 02/06/2023] Open
Abstract
A newly identified coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which causes the infectious coronavirus disease 2019 (COVID‐19), emerged in December 2019 in Wuhan, Hubei Province, China, and now poses a major threat to global public health. Previous studies have observed highly variable alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in patients with COVID‐19. However, circulating levels of the cholangiocyte injury biomarker gamma‐glutamyltransferase (GGT) have yet to be reported in the existing COVID‐19 case studies. Herein, we describe the relationship between GGT levels and clinical and biochemical characteristics of patients with COVID‐19. Our study is a retrospective case series of 98 consecutive hospitalized patients with confirmed COVID‐19 at Wenzhou Central Hospital in Wenzhou, China, from January 17 to February 5, 2020. Clinical data were collected using a standardized case report form. Diagnosis of COVID‐19 was assessed by symptomatology, reverse‐transcription polymerase chain reaction (RT‐PCR), and computed tomography scan. The medical records of patients were analyzed by the research team. Of the 98 patients evaluated, elevated GGT levels were observed in 32.7%; increased C‐reactive protein (CRP) and elevated ALT and AST levels were observed in 22.5%, 13.3%, and 20.4%, respectively; and elevated alkaline phosphatase (ALP) and triglycerides (TGs) were found in 2% and 21.4%, respectively. Initially, in the 82 patients without chronic liver disease and alcohol history, age older than 40 years (P = 0.027); male sex (P = 0.0145); elevated CRP (P = 0.0366), ALT (P < 0.0001), and ALP (P = 0.0003); and increased TGs (P = 0.0002) were found to be associated with elevated GGT levels. Elevated GGT (P = 0.0086) and CRP (P = 0.0162) levels had a longer length of hospital stay. Conclusion: A sizable number of patients with COVID‐19 infection have elevated serum GGT levels. This elevation supports involvement of the liver in persons with COVID‐19.
Collapse
Affiliation(s)
- Tuo Shao
- Liver Center and Gastrointestinal DivisionDepartment of MedicineMassachusetts General HospitalHarvard Medical SchoolBostonMA
| | - Yu Tong
- Department of Clinical LaboratoryWenzhou People’s HospitalThe Third Clinical Institute Affiliated to Wenzhou Medical UniversityWenzhouChina
| | - Shushu Lu
- Department of Infectious DiseasesWenzhou Central Hospital and Sixth People’s Hospital of WenzhouWenzhouChina
| | - Andre J. Jeyarajan
- Liver Center and Gastrointestinal DivisionDepartment of MedicineMassachusetts General HospitalHarvard Medical SchoolBostonMA
| | - Feifei Su
- Department of Infectious DiseasesWenzhou Central Hospital and Sixth People’s Hospital of WenzhouWenzhouChina
| | - Jianyi Dai
- Department of Infectious DiseasesWenzhou Central Hospital and Sixth People’s Hospital of WenzhouWenzhouChina
| | - Jichan Shi
- Department of Infectious DiseasesWenzhou Central Hospital and Sixth People’s Hospital of WenzhouWenzhouChina
| | - Jianping Huang
- Department of Infectious DiseasesWenzhou Central Hospital and Sixth People’s Hospital of WenzhouWenzhouChina
| | - Chenchan Hu
- Department of Infectious DiseasesWenzhou Central Hospital and Sixth People’s Hospital of WenzhouWenzhouChina
| | - Lianpeng Wu
- Department of Infectious DiseasesWenzhou Central Hospital and Sixth People’s Hospital of WenzhouWenzhouChina
| | - Xianning Dai
- Department of Clinical LaboratoryWenzhou People’s HospitalThe Third Clinical Institute Affiliated to Wenzhou Medical UniversityWenzhouChina
| | - Zhimeng Cheng
- Liver Center and Gastrointestinal DivisionDepartment of MedicineMassachusetts General HospitalHarvard Medical SchoolBostonMA
| | - Jiuliang Yan
- Liver Center and Gastrointestinal DivisionDepartment of MedicineMassachusetts General HospitalHarvard Medical SchoolBostonMA
| | - Peng Huang
- Liver Center and Gastrointestinal DivisionDepartment of MedicineMassachusetts General HospitalHarvard Medical SchoolBostonMA
| | - Yanzhang Tian
- Liver Center and Gastrointestinal DivisionDepartment of MedicineMassachusetts General HospitalHarvard Medical SchoolBostonMA
| | - Shasha Li
- Department of HepatologyNo. 2 People’s Hospital of Fuyang CityFuyangChina
| | - Raymond T. Chung
- Liver Center and Gastrointestinal DivisionDepartment of MedicineMassachusetts General HospitalHarvard Medical SchoolBostonMA
| | - Dong Chen
- Department of Infectious DiseasesWenzhou Central Hospital and Sixth People’s Hospital of WenzhouWenzhouChina
| |
Collapse
|
29
|
Chen D, Li X, Song Q, Hu C, Su F, Dai J, Ye Y, Huang J, Zhang X. Assessment of Hypokalemia and Clinical Characteristics in Patients With Coronavirus Disease 2019 in Wenzhou, China. JAMA Netw Open 2020; 3:e2011122. [PMID: 32525548 PMCID: PMC7290402 DOI: 10.1001/jamanetworkopen.2020.11122] [Citation(s) in RCA: 148] [Impact Index Per Article: 37.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
IMPORTANCE Severe acute respiratory syndrome coronavirus 2 has caused a global outbreak of coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 binds angiotensin-converting enzyme 2 of the rennin-angiotensin system, resulting in hypokalemia. OBJECTIVE To investigate the prevalence, causes, and clinical implications of hypokalemia, including its possible association with treatment outcomes, among patients with COVID-19. DESIGN, SETTING, AND PARTICIPANTS This cohort study was conducted at Wenzhou Central Hospital and Sixth People's Hospital of Wenzhou, Wenzhou, China, from January 11, 2020, to February 15, 2020. Participants included patients who received a diagnosis of COVID-19 according to the criteria issued by the Chinese Health Bureau and were admitted to the hospital. The patients were classified as having severe hypokalemia (plasma potassium <3 mmol/L), hypokalemia (plasma potassium 3-3.5 mmol/L), and normokalemia (plasma potassium >3.5 mmol/L). The clinical features, therapy, and outcomes were compared between the 3 groups. Data analysis was conducted in March 2020. INTERVENTIONS The patients were given general support and antiviral therapy. Their epidemiological and clinical features were collected. MAIN OUTCOMES AND MEASURES The prevalence of hypokalemia and response to treatment with potassium supplements were measured by analyzing plasma and urine potassium levels. RESULTS One hundred seventy-five patients (87 female patients [50%]; mean [SD] age, 45 [14] years) were classified as having severe hypokalemia (31 patients [18%]), hypokalemia (64 patients [37%]), and normokalemia (80 patients [46%]). Patients with severe hypokalemia had statistically significantly higher body temperature (mean [SD], 37.6 °C [0.9 °C]) than the patients with hypokalemia (mean [SD], 37.2 °C [0.7 °C]; difference, 0.4 °C; 95% CI, 0.2-0.6 °C; P = .02) and the patients with normokalemia (mean [SD], 37.1 °C [0.8 °C]; difference, 0.5 °C; 95% CI, 0.3-0.7 °C; P = .005). Patients with higher levels of hypokalemia also had higher creatine kinase levels (severe hypokalemia, mean [SD], 200 [257] U/L [median, 113 U/L; interquartile range {IQR}, 61-242 U/L]; hypokalemia, mean [SD], 97 [85] U/L; and normokalemia, mean [SD], 82 [57] U/L), higher creatine kinase-MB fraction (severe hypokalemia, mean [SD], 32 [39] U/L [median, 14 U/L; IQR, 11-36 U/L]; hypokalemia, mean [SD], 18 [15] U/L; and normokalemia, mean [SD], 15 [8] U/L), higher lactate dehydrogenase levels (mean [SD], severe hypokalemia, 256 [88] U/L; hypokalemia, 212 [59] U/L; and normokalemia, 199 [61] U/L), and higher C-reactive protein levels (severe hypokalemia, mean [SD], 29 [23] mg/L; hypokalemia, mean [SD], 18 [20] mg/L [median, 12, mg/L; IQR, 4-25 mg/L]; and normokalemia, mean [SD], 15 [18] mg/L [median, 6 U/L; IQR, 3-17 U/L]). Of 40 severely and critically ill patients, 34 (85%) had hypokalemia. Patients with severe hypokalemia were given potassium at a dose of 40 mEq per day, for a total mean (SD) of 453 (53) mEq potassium chloride, during the hospital stay. The patients responded well to potassium supplements as they recovered. CONCLUSIONS AND RELEVANCE The correction of hypokalemia is challenging because of continuous renal potassium loss resulting from the degradation of angiotensin-converting enzyme 2. The high prevalence of hypokalemia among patients with COVID-19 suggests the presence of disordered rennin-angiotensin system activity, which increases as a result of reduced counteractivity of angiotensin-converting enzyme 2, which is bound by severe acute respiratory syndrome coronavirus 2.
Collapse
Affiliation(s)
- Dong Chen
- Department of Infectious Diseases, The Ding Li Clinical College of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
- Department of Infectious Diseases, Sixth People’s Hospital of Wenzhou, Wenzhou, Zhejiang Province, China
| | - Xiaokun Li
- Virus Research Institute, Wenzhou Medical University, Wenzhou, Zhejiang Province, China
| | - Qifa Song
- Department of Microbiology, Ningbo Municipal Centre for Disease Control and Prevention, Ningbo, Zhejiang Province, China
| | - Chenchan Hu
- Department of Infectious Diseases, The Ding Li Clinical College of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
- Department of Infectious Diseases, Sixth People’s Hospital of Wenzhou, Wenzhou, Zhejiang Province, China
| | - Feifei Su
- Department of Infectious Diseases, The Ding Li Clinical College of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
- Department of Infectious Diseases, Sixth People’s Hospital of Wenzhou, Wenzhou, Zhejiang Province, China
| | - Jianyi Dai
- Department of Infectious Diseases, The Ding Li Clinical College of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
- Department of Infectious Diseases, Sixth People’s Hospital of Wenzhou, Wenzhou, Zhejiang Province, China
| | - Yinghai Ye
- Department of Infectious Diseases, The Ding Li Clinical College of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
- Department of Infectious Diseases, Sixth People’s Hospital of Wenzhou, Wenzhou, Zhejiang Province, China
| | - Jianping Huang
- Department of Infectious Diseases, The Ding Li Clinical College of Wenzhou Medical University, Wenzhou, Zhejiang Province, China
- Department of Infectious Diseases, Sixth People’s Hospital of Wenzhou, Wenzhou, Zhejiang Province, China
| | - Xiaoming Zhang
- Department of Microbiology, Wenzhou Municipal Centre for Disease Control and Prevention, Wenzhou, Zhejiang Province, China
| |
Collapse
|
30
|
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2019; 30:1842. [PMID: 31407010 PMCID: PMC6927326 DOI: 10.1093/annonc/mdz215] [Citation(s) in RCA: 36] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Guo R, Su F, Wang H, Guo Y, Yao H, Huang G, Li J, Liang Z, Shi K, Ma S. Luminescence Tuning of Layered Rare-Earth Hydroxides (LRHs, R = Tb, Y) Composites with 3-Hydroxy-2-naphthoic Acid and Application to the Fluorescent Detection of Al 3. Inorg Chem 2019; 58:4979-4988. [PMID: 30933488 DOI: 10.1021/acs.inorgchem.8b03636] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Tunable luminescence (quenching or blue shift) of HNA/OS-LRH composites (HNA is 3-hydroxy-2-naphthoic acid; OS is the anionic surfactant of 1-octanesulfonic acid sodium; LRHs are layered rare-earth hydroxides, R = Tb3+, Y3+) in the solid state and delaminated state is reported, which is utilized as an effective fluorescent probe for detecting metal ions. HNA/OS species are intercalated into LRH layers to generate composites of HNA xOS1- x-LTbH ( x = 0.10, 0.15, 0.20 , 0.25) and HNA yOS1- y-LYH ( y = 0.05, 0.10, 0.15, 0.20, 0.25, 0.30). In the solid state, LYH composites exhibit green emissions (from 493 to 504 nm) with a large blue shift in comparison to the 542 nm emission of free HNA- anions, while in the delaminated state in formamide (FM), the composites display blue emission (480 nm) relative to the green emission (512 nm) of an HNA soltuion in FM. However, LTbH composites display coquenched luminescence in both the solid state and delaminated state. Also, HNA0.25OS0.75-1:1-LYH, HNA0.25OS0.75-1:2-LYH, and HNA0.05OS0.95-1:1-LYH (1:1 and 1:2 are HNA:NaOH molar ratios) show significantly elongated fluorescence lifetimes of 15.35, 14.37, and 12.72 ns, respectively, in comparison with free HNA-Na (6.44 ns), and their quantum yields of 23.40%, 21.97%, and 22.31%, respectively, are much larger than that of free HNA-Na (4.86%). The LTbH composite (HNA0.25OS0.75-1:1-LTbH) has also a relatively higher quantum yield of 12.46%. The HNA0.25OS0.75-1:1-LYH colloid exhibits excellent recognition selectivity for Al3+ over other metal ions (Mg2+, Co2+, Ni2+, Cu2+, Zn2+, Pb2+, Cd2+, and Hg2+) with distinct fluorescence sensitization. It shows an intense change in its fluorescence emission when it is bound to Al3+ ions, giving a lower detection limit of 6.32 × 10-6 M. This is novel research on the fluorescence chemosensing of LRH composites.
Collapse
Affiliation(s)
- Rong Guo
- Beijing Key Laboratory of Energy Conversion and Storage Materials, College of Chemistry , Beijing Normal University , Beijing 100875 , People's Republic of China
| | - Feifei Su
- Beijing Key Laboratory of Energy Conversion and Storage Materials, College of Chemistry , Beijing Normal University , Beijing 100875 , People's Republic of China
| | - Hui Wang
- Beijing Key Laboratory of Energy Conversion and Storage Materials, College of Chemistry , Beijing Normal University , Beijing 100875 , People's Republic of China
| | - Yuexin Guo
- School of Pharmacy , North China University of Science and Technology , Tangshan 063210 , People's Republic of China
| | - Huiqin Yao
- School of Basic Medical Sciences , Ningxia Medical University , Yinchuan 750004 , People's Republic of China
| | - Gailing Huang
- School of Materials and Chemical Engineering , Zhengzhou University of Light Industry , Zhengzhou 450001 , People's Republic of China
| | - Jian Li
- Chemistry & Chemical and Environmental Engineering College , Weifang University , Weifang 261061 , People's Republic of China
| | - Zupei Liang
- Chemistry & Chemical and Environmental Engineering College , Weifang University , Weifang 261061 , People's Republic of China
| | - Keren Shi
- State Key Laboratory of High-efficiency Utilization of Coal and Green Chemical Engineering , Ningxia University , Yinchuan 750021 , People's Republic of China
| | - Shulan Ma
- Beijing Key Laboratory of Energy Conversion and Storage Materials, College of Chemistry , Beijing Normal University , Beijing 100875 , People's Republic of China
| |
Collapse
|
32
|
Zhou CY, Su F, Zhang BX, Han C. Crystal and Molecular Structures of Two Salts Based on Polyamine Deribatives. J STRUCT CHEM+ 2019. [DOI: 10.1134/s0022476619020203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
33
|
Lai J, Pan Z, Deng H, Peng J, Chen P, Ye G, Yu F, Zeng M, Chen K, Su F. Personalized prognostic model incorporating axillary lymph node ratio and molecular subtype for predicting long-term survival in node-positive patients with breast cancer: A large-scale, multicenter study. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy426.001] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Lai J, Peng J, Deng H, Chen P, Ye G, Yu F, Su F, Chen K, Pan Z. Prognostic nomogram based on lymph node ratio to predict survival in node-positive breast cancer patients treated with neoadjuvant chemotherapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy427.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Lai J, Pan Z, Deng H, Peng J, Chen P, Ye G, Yu F, Chen K, Su F. Prognostic nomograms for predicting overall and cancer-specific survival in breast cancer patients not achieving pathological complete response after neoadjuvant chemotherapy. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy427.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Yap Y, Masuda N, Ito Y, Ishikawa T, Kim S, Aruga T, Toyama T, Saeki T, Yamanaka T, Saito M, Watanabe J, Takahashi M, Nakamura S, Inoue K, Suarez-Vizcarra J, He W, Solovieff N, Su F, Chiu J. Biomarker analyses of Asian women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC) receiving ribociclib (RIB) + endocrine therapy (ET). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy428.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
37
|
Neven P, Petrakova K, Bianchi G, De La Cruz Merino L, Jerusalem G, Beck J, Sonke G, Chia S, Brucker S, Wang Y, He W, Rodriguez Lorenc K, Su F, Im SA. Ribociclib (RIB) + fulvestrant (FUL) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-3 biomarker analyses. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy272.336] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Su F, Guo R, Yu Z, Li J, Liang Z, Shi K, Ma S, Sun G, Li H. Layered rare-earth hydroxide (LRH, R = Tb, Y) composites with fluorescein: delamination, tunable luminescence and application in chemosensoring for detecting Fe(iii) ions. Dalton Trans 2018; 47:5380-5389. [PMID: 29589632 DOI: 10.1039/c8dt00409a] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
We demonstrate a novel example of tunable luminescence and the application of the delaminated FLN/OS-LRH composites (LRHs are layered rare-earth hydroxides, R = Tb, Y; FLN is the fluorescein named 2-(6-hydroxy-3-oxo-(3H)-xanthen-9-yl)benzoic acid; OS is the anionic surfactant 1-octane sulfonic acid sodium) in detecting Fe(iii) ions. The FLNxOS1-x species (x = 0.02, 0.05, 0.10, and 0.20) are intercalated into the LTbyY1-yH layers (y = 1, 0.9, 0.7, 0.5, 0.3, 0.1 and 0) by ion exchange reactions to yield the composites FLNxOS1-x-LTbyY1-yH. In the solid state, the LYH composites display green emission (564 nm) arising from the organic FLN, while in LTbH composites, the luminescence of the Tb3+ in the layers (545 nm) and the FLN in the interlayers is co-quenched. In the delaminated state in formamide (FM), FLNxOS1-x-LTbH composites display green to yellowish-green luminescence (540-574 nm) following the increasing FLN/OS ratio; while the FLN0.02OS0.98-LTbyY1-yH composites show green emission at ∼540 nm. The fluorescence lifetimes of the composites (4.22-4.63 ns) are comparable to the free FLN-Na, and the quantum yields (31.62-78.70%) of the composites especially that (78.70%) of the FLN0.02OS0.98-LYH are much higher than that (28.40%) of free FLN-Na. The recognition ability of the FLN0.02OS0.98-LYH composite for metal cations is researched. The delaminated FLN0.02OS0.98-LYH colloidal suspension exhibits high selectivity for Fe3+ over other ions (Mg2+, Al3+, Ni2+, Co2+, Cu2+, Zn2+, Mn2+, Pb2+, and Cd2+) with fluorescence quenching, which can work as a kind of turn-off fluorescence sensor for the detection of Fe3+. The detection limit of Fe3+ is determined to be 2.58 × 10-8 M and the quenching constant (Ksv) is 1.70 × 103 M-1. This is the first work on LRH materials working as a chemosensor for recognising metal cations. It provides a new approach for the design of LRH materials to be applied in fluorescence chemosensing.
Collapse
Affiliation(s)
- Feifei Su
- Beijing Key Laboratory of Energy Conversion and Storage Materials, College of Chemistry, Beijing Normal University, Beijing 100875, P. R. China.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Su F, Miao J, Liu X, Wei X, Yu X. Distal myopathy with rimmed vacuoles: Spectrum of GNE gene mutations in seven Chinese patients. Exp Ther Med 2018; 16:1505-1512. [PMID: 30112071 DOI: 10.3892/etm.2018.6344] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2017] [Accepted: 06/04/2018] [Indexed: 11/06/2022] Open
Abstract
Distal myopathy with rimmed vacuoles (DMRV) is a rare, autosomal, recessive inherited disease caused by mutations in the GNE gene. DMRV is an adult-onset disorder characterized by progressive muscle atrophy and weakness, which initially involves the distal muscles with quadriceps sparing. To date, >150 GNE mutations have been reported in different populations from around the world. The present study investigated the clinical, pathological and genetic characteristics of seven unrelated DMRV patients from China. Genetic analysis in these patients revealed three novel mutations (c.455_456insC, p.P421L, and p.A287T) and five previously reported mutations (p.D207V, p.C44S, p.G576R, p.A669P, and p.D218G). In addition, the literature on DMRV was reviewed to provide an overview of the disease and broaden the mutational spectrum of the GNE gene in China.
Collapse
Affiliation(s)
- Feifei Su
- Department of Neurology, Neuroscience Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Jing Miao
- Department of Neurology, Neuroscience Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Xuemei Liu
- Department of Neurology, Neuroscience Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Xiaojing Wei
- Department of Neurology, Neuroscience Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| | - Xuefan Yu
- Department of Neurology, Neuroscience Center, The First Affiliated Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
| |
Collapse
|
40
|
Su F, He E, Qian L, Zhu Z, Wei L, Zeng Z, Qu W, Xu R, Yi Z. Complication Follow-up With Ultrasonographic Analyses of 91 Cases With Donor Gallbladder Preservation in Living Donor Liver Transplantation of Left Lateral Sectionectomies. Transplant Proc 2018; 50:217-221. [PMID: 29407312 DOI: 10.1016/j.transproceed.2017.12.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2017] [Revised: 10/22/2017] [Accepted: 12/05/2017] [Indexed: 02/08/2023]
Abstract
BACKGROUND Preserving the donor's gallbladder during living donor liver transplantation (LDLT) is a better method for liver transplantation surgery, but not enough is known about gallbladder complications after the operation. METHODS We retrospectively investigated postsurgical donor gallbladder complications in clinical LDLT with gallbladder preservation. The feasibility of retaining the gallbladder during liver graft procurement is discussed. Ninety-one donors with retained gallbladder after LDLT with the hepatic left lateral sectionectomy (from June 2013 to October 2015) were retrospectively analyzed. Donors were followed for 12.6 to 40.7 months after surgery (median 26.1 months). Sonography was used to evaluate gallbladder characteristics before and after surgery. RESULTS Gallbladder function had recovered to almost normal 1 month after transplantation. Four donors (4.40%) experienced gallbladder enlargement that resolved after 3 days. Thickening of the gallbladder wall in 31 donors (34.07%) was restored within 2 to 75 days. Biliary sludge appeared in 9 donors (9.89%); 6 of them recovered within 3 to 34 days. Three (3.30%) and 1 donor (1.10%) suffered gallstone and gallbladder polyps, respectively, which persisted until the last follow-up. CONCLUSION The rate of postoperative complications of the gallbladder in donors was relative low. Preserving the gallbladder in liver transplantation donors during liver graft procurement is feasible and safe.
Collapse
Affiliation(s)
- F Su
- Department of Ultrasound, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China
| | - E He
- Department of Ultrasound, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China
| | - L Qian
- Department of Ultrasound, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China.
| | - Z Zhu
- Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - L Wei
- Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - Z Zeng
- Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - W Qu
- Department of General Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China
| | - R Xu
- Department of Ultrasound, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China
| | - Z Yi
- Department of Ultrasound, Beijing Friendship Hospital Affiliated to Capital Medical University, Beijing, China
| |
Collapse
|
41
|
Hortobagyi G, Stemmer S, Burris H, Yap Y, Sonke G, Paluch-Shimon S, Campone M, Petrakova K, Blackwell K, Winer E, Janni W, Verma S, Conte P, Arteaga C, Cameron D, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O’Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018; 29:1541-1547. [DOI: 10.1093/annonc/mdy155] [Citation(s) in RCA: 356] [Impact Index Per Article: 59.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
42
|
Olson M, Helfenbein E, Su L, Berg M, Knight L, Troy L, Sacks L, Sakai D, Su F. Variability in the time to initiation of CPR in continuously monitored pediatric ICUs. Resuscitation 2018; 127:95-99. [PMID: 29605703 DOI: 10.1016/j.resuscitation.2018.03.033] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2017] [Revised: 03/17/2018] [Accepted: 03/26/2018] [Indexed: 11/29/2022]
Abstract
AIM To study the influence of patient characteristics and unit ergonomics and human factors on the time to initiation of CPR. METHODS A single center study of children, 0 to 21 years old, admitted to an ICU who experienced cardiopulmonary arrest (CPA) requiring >1 min of chest compressions. Time of CPA was determined by analysis of continuous ECG, plethysmography, arterial blood pressure, and end-tidal CO2 (EtCO2) waveforms. Initiation of CPR was identified by the onset of cyclic artifact in the ECG waveform. Patient characteristics and unit ergonomics and human factors were examined including CPA cause, identification on the High-Risk Checklist (HRC), existing monitoring, ICU type, time of day, nursing shift change, and outcome. RESULTS The median time from CPA to initiation of CPR was 50.5 s (IQR 26.5 to 127.5) in 36 CPAs. Forty-seven percent of patients experienced time from CPA to initiation of CPR of >1 min. There was no difference in CPA cause, ICU type, time of day, or nursing shift change. CONCLUSION Nearly half of pediatric patients who experienced CPA in an ICU setting did not meet AHA guidelines for early initiation of CPR. This is an opportunity to study the recognition phase of CPA using continuous monitoring data with the aim of improving the understanding of and factors contributing to delays in initiation of CPR.
Collapse
Affiliation(s)
- M Olson
- Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA.
| | | | - L Su
- Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
| | - M Berg
- Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
| | - L Knight
- Stanford Children's Health, Palo Alto, CA, USA
| | - L Troy
- Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
| | - L Sacks
- Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
| | - D Sakai
- Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
| | - F Su
- Department of Pediatrics, Stanford University School of Medicine, Stanford, CA, USA
| | | |
Collapse
|
43
|
Pan X, Yang S, Deighton MA, Qu Y, Hong L, Su F. A Comprehensive Evaluation of Xpert MTB/RIF Assay With Bronchoalveolar Lavage Fluid as a Single Test or Combined With Conventional Assays for Diagnosis of Pulmonary Tuberculosis in China: A Two-Center Prospective Study. Front Microbiol 2018; 9:444. [PMID: 29593688 PMCID: PMC5859353 DOI: 10.3389/fmicb.2018.00444] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Accepted: 02/26/2018] [Indexed: 11/13/2022] Open
Abstract
Introduction: The Xpert MTB/RIF is recommended by the World Health Organization as a first line rapid test for the diagnosis of pulmonary tuberculosis (TB); however, China does not routinely use this test, partially due to the lack of a sufficient number of systematic evaluations of this assay in local patients. The aims of this study were to comprehensively assess the diagnostic performance of Xpert MTB/RIF, either alone or in combination with conventional assays for the diagnosis of pulmonary TB in adult Chinese patients. Methods: Xpert MTB/RIF tests were performed in 190 adult patients with suspected pulmonary TB, using bronchoalveolar lavage fluid (BALF) as test specimens. In parallel, conventional tests were carried out using the same BALF samples. Using two different reference standards, the performance of Xpert MTB/RIF, conventional assays and their combinations were evaluated. Results: Using mycobacterial culture as the reference comparator, Xpert MTB/RIF was found to be superior to smear-microscopy in detecting Mycobacterium tuberculosis. When final diagnosis, based on clinical criteria, was employed as the reference standard, Xpert MTB/RIF showed an even higher accuracy of 72.1%, supported by a sensitivity of 61.1% and specificity of 96.6%. Xpert MTB/RIF also demonstrated a powerful capability to identify pulmonary TB cases undetected by culture or smear-microscopy. Combining smear-microscopy and Xpert MTB/RIF was found to be the most accurate early predictor for pulmonary TB. Rifampicin resistance reported by Xpert MTB/RIF slightly deviated from that by phenotypic antibiotic susceptibility testing and requires further study with a larger sample size. Conclusion: This two-center prospective study highlights the value of Xpert MTB/RIF with BALF in diagnosing pulmonary TB in adult Chinese patients. These findings might contribute to the optimization of current diagnostic algorithms for pulmonary TB in China.
Collapse
Affiliation(s)
- Xiaofu Pan
- Department of Laboratory Medicine, The Third Affiliated Hospital of the Wenzhou Medical University, Rui'an, China
| | - Shoufeng Yang
- Department of Infectious Diseases, Wenzhou Central Hospital, Zhejiang, China
| | | | - Yue Qu
- Department of Laboratory Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.,Biomedicine Discovery Institute, Department of Microbiology, School of Medicine, Nursing and Health Sciences, Monash University, Clayton, VIC, Australia
| | - Liang Hong
- Department of Infectious Diseases, The Third Affiliated Hospital of Wenzhou Medical University, Rui'an, China
| | - Feifei Su
- Department of Infectious Diseases, Wenzhou Central Hospital, Zhejiang, China
| |
Collapse
|
44
|
Hortobagyi GN, Stemmer S, Campone M, Sonke GS, Arteaga CL, Paluch-Shimon S, Petrakova K, Villanueva C, Nusch A, Grischke EM, Chan A, Jakobsen E, Marschner N, Hart LL, Alba E, Ohnstand HO, Blau S, Yardley DA, Solovieff N, Su F, Germa C, Yap YS. Abstract PD4-06: First-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-pd4-06] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The addition of first-line ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor) to letrozole (LET) significantly improved progression-free survival (PFS) compared with placebo (PBO) + LET in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in the Phase III MONALEESA-2 study. Identifying biomarkers that predict response to treatment remains a key challenge in pts with HR+ ABC. Here we analyze results from MONALEESA-2 by molecular alterations detected in circulating tumor DNA (ctDNA) at baseline, including PIK3CA mutations and other alterations considered to be important in HR+ ABC.
Methods: Postmenopausal women (N=668) with HR+, HER2– ABC who had not received any prior therapy for ABC were randomized 1:1 to RIB (600 mg/day; 3-weeks-on/1-week-off) + LET (2.5 mg/day; continuous) or PBO + LET. The primary endpoint was PFS. Biomarker analysis of the ctDNA mutation profile was an exploratory endpoint. Plasma samples for ctDNA analysis were collected at baseline and end of treatment. ctDNA was analyzed using next-generation sequencing with a targeted panel of ˜550 genes.
Results: Baseline ctDNA was successfully sequenced in 494 pts (RIB + LET: n=212; PBO + LET: n=215); 67 (14%) of 494 pts were removed from the analysis due to limited tumor DNA in circulation. 427 (86%) pts had ≥1 alteration, including 1,573 mutations, 513 short insertions/deletions, 166 amplifications, and 8 translocations. Alterations (frequency) were commonly observed in the following genes: PIK3CA (33%), TP53 (12%), ZNF703/FGFR1 (5%), and ESR1 (4%), and in genes involved in receptor tyrosine kinase (RTK) signaling (12%). RIB + LET treatment benefit was consistent in pts with wild-type (WT) and altered PIK3CA, and in pts with WT and altered TP53 (Table). RIB + LET improved PFS regardless of RTK or ZNF703/FGFR1 alterations. However, there was a weak trend for increased benefit in pts with WT vs altered RTK genes and in pts with WT vs altered ZNF703/FGFR1 genes. These results should be interpreted with caution due to the small number of pts with these alterations. There were too few ESR1 alterations for firm conclusions to be drawn.
Events, n/NMedian PFS, months Gene(s)RIB + LETPBO + LETRIB + LETPBO + LETHazard ratio (95% confidence interval)PIK3CAWT54/14393/14229.614.70.44 (0.31–0.62)Altered40/6955/7319.212.70.53 (0.35–0.81)TP53WT72/180129/19427.614.70.44 (0.33–0.59)Altered22/3219/2110.25.50.43 (0.23–0.83)ZNF703/FGFR1WT88/202139/20524.814.60.47 (0.36–0.62)Altered6/109/1010.611.40.73 (0.23–2.29)RTKWT81/189128/18724.814.40.46 (0.35–0.61)Altered13/2320/2821.311.40.72 (0.34–1.53)
Conclusions: Consistent RIB + LET treatment benefit was observed compared with PBO + LET, irrespective of the status of baseline ctDNA biomarkers.
Citation Format: Hortobagyi GN, Stemmer S, Campone M, Sonke GS, Arteaga CL, Paluch-Shimon S, Petrakova K, Villanueva C, Nusch A, Grischke E-M, Chan A, Jakobsen E, Marschner N, Hart LL, Alba E, Ohnstand HO, Blau S, Yardley DA, Solovieff N, Su F, Germa C, Yap Y-S. First-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2 [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr PD4-06.
Collapse
Affiliation(s)
- GN Hortobagyi
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - S Stemmer
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - M Campone
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - GS Sonke
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - CL Arteaga
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - S Paluch-Shimon
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - K Petrakova
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - C Villanueva
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - A Nusch
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - E-M Grischke
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - A Chan
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - E Jakobsen
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - N Marschner
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - LL Hart
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - E Alba
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - HO Ohnstand
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - S Blau
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - DA Yardley
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - N Solovieff
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - F Su
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - C Germa
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| | - Y-S Yap
- The University of Texas MD Anderson Cancer Center, Houston, TX; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv, Israel; Institut de Cancérologie de l'Ouest – René Gauducheau Centre de Recherche en Cancérologie, Nates, France; Netherlands Cancer Institute and BOOG Study Center, Amsterdam, Netherlands; Vanderbilt-Ingram Cancer Center, Nashville, TN; Sheba Medical Center, Ramat Gan, Israel; Masaryk Memorial Cancer Institute, Brno, Czech Republic; University Hospital of Besançon, Hospital Jean-Minjoz, Besançon, France; Onkologische Praxis Velbert, Velbert, Germany; University of Tübingen, Tübingen, Germany; Breast Cancer Research Centre–Western Australia and Curtin University, Perth, Australia; Vejle Hospital, Vejle, Denmark; Joint Practice for Interdisciplinary Oncology and Hematology, Freiburg, Germany; Florida Cancer Specialists–Sarah Cannon Research Institute, Fort Myers, FL; Hospital Universitario Virgen de la Victoria, IBIMA, Málaga, Spain; Norwegian Radium Hospital, Oslo University H
| |
Collapse
|
45
|
Su F, Shi M, Zhang J, Zheng Q, Zhang D, Zhang W, Wang H, Li X. Simvastatin Protects Heart from Pressure Overload Injury by Inhibiting Excessive Autophagy. Int J Med Sci 2018; 15:1508-1516. [PMID: 30443172 PMCID: PMC6216062 DOI: 10.7150/ijms.28106] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2018] [Accepted: 08/29/2018] [Indexed: 12/12/2022] Open
Abstract
Cardiac hypertrophy is an independent predictor of cardiovascular morbidity and mortality. To identify the mechanisms by which simvastatin inhibits cardiac hypertrophy induced by pressure overload, we determined effects of simvastatin on 14-3-3 protein expression and autophagic activity. Simvastatin was administered intragastrically to Sprague-Dawley (SD) rats before abdominal aortic banding (AAB). Neonatal rat cardiomyocytes (NRCs) were treated with simvastatin before angiotensin II (AngII) stimulation. 14-3-3, LC3, and p62 protein levels were determined by western blot. Autophagy was also measured by the double-labeled red fluorescent protein-green fluorescent protein autophagy reporter system. Simvastatin alleviated excessive autophagy, characterized by a high LC3II/LC3I ratio and low level of p62, and blunted cardiac hypertrophy while increasing 14-3-3 protein expression in rats that had undergone AAB. In addition, it increased 14-3-3 expression and inhibited excessive autophagy in NRCs exposed to AngII. Our study demonstrated that simvastatin may inhibit excessive autophagy, increase 14-3-3 expression, and finally exert beneficial effects on cardioprotection against pressure overload.
Collapse
Affiliation(s)
- Feifei Su
- Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, China
| | - Miaoqian Shi
- Department of Cardiology, PLA Army General Hospital, No.5 Nanmen Cang, Dongcheng District, Beijing, 100700, China
| | - Jian Zhang
- Department of Cardiology, Beijing Chest Hospital Heart Center, Capital Medical University, No.9. Beiguan Grand Street, Tongzhou District, Beijing, 101149, China
| | - Qiangsun Zheng
- Division of Cardiology, Second Affiliated Hospital of JiaoTong University, Xi'an, 710004, China
| | - Dongwei Zhang
- Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, China
| | - Wei Zhang
- Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, China
| | - Haichang Wang
- Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, China
| | - Xue Li
- Department of Cardiology, Tangdu Hospital, Fourth Military Medical University, Xi'an, 710038, China
| |
Collapse
|
46
|
Galliano A, Ye C, Su F, Wang C, Wang Y, Liu C, Wagle A, Guerin M, Flament F, Steel A. Particulate matter adheres to human hair exposed to severe aerial pollution: consequences for certain hair surface properties. Int J Cosmet Sci 2017; 39:610-616. [PMID: 28748540 DOI: 10.1111/ics.12416] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2017] [Accepted: 06/29/2017] [Indexed: 01/23/2023]
Abstract
BACKGROUND The deposit and adherence of particulate matter (PM) from aerial pollution onto the surface of human hair is a poorly studied phenomenon. OBJECTIVES (i) To reproduce in vitro the deposit of known PM on standardized hair swatches in a closed box, (ii) to compare in vitro data with those obtained under 'real-life' conditions of severe aerial pollution and (iii) to assess the changes of the hair surface properties, potentially caused by the adherence of airborne PM onto the hair. METHODS In vitro: a PM was sprayed onto untreated or sebum-coated hair swatches. Real-life conditions: other swatches were exposed to a severely polluted environment, for 24 to 72 h, in Baoding (PR China). In both cases, swatches were examined using scanning electron microscopy. The shine, the frictional properties and the level of metals were measured and compared to those same properties for the unexposed swatches. RESULTS This work clearly indicates that, under real-life conditions, a large number of PM of various sizes are deposited onto the hair surface. This phenomenon is increased by the presence of sebum and longer exposure times. The in vitro level of PM deposited onto the hair surface is comparable to the in vivo level. The presence of sebum seems to favour the deposit of larger PM. The shine of the exposed swatches is significantly decreased, whereas their respective friction coefficients are significantly increased. Both the presence of sebum and length of exposure time increased the amount of analysed metals present on the exposed hair surface (Al, Fe, Cu, Ba and Zn). CONCLUSION This work indicates that a very high amount (e.g. billions) of PM can be deposited on a full head of hair for subjects living in a severely aerially polluted environment. This process can be reproduced in vitro. In real-life, pollution has a strong impact on hair surface properties, leading to a modification of the visual aspect (loss of shine) and the alteration of hair surface (increase in friction force). This work may be used to pave the way for prevention and cleansing studies in the field of hair care.
Collapse
Affiliation(s)
- A Galliano
- L'Oréal Research and Innovation, Centre Charles Zviak, Saint-Ouen, France
| | - C Ye
- L'OREAL (China) R&D Center Pudong, Shanghai, China
| | - F Su
- L'OREAL (China) R&D Center Pudong, Shanghai, China
| | - C Wang
- L'OREAL (China) R&D Center Pudong, Shanghai, China
| | - Y Wang
- L'OREAL (China) R&D Center Pudong, Shanghai, China
| | - C Liu
- L'OREAL (China) R&D Center Pudong, Shanghai, China
| | - A Wagle
- L'OREAL (India) R&D Center Maharashtra, Mumbai, India
| | - M Guerin
- L'Oréal Research and Innovation, Centre Charles Zviak, Saint-Ouen, France
| | - F Flament
- L'Oréal Research and Innovation, Centre Charles Zviak, Saint-Ouen, France
| | - A Steel
- L'OREAL (China) R&D Center Pudong, Shanghai, China
| |
Collapse
|
47
|
Dong Q, Xing W, Su F, Liang X, Tian F, Gao F, Wang S, Zhang H. Tetrahydroxystilbene Glycoside Improves Microvascular Endothelial Dysfunction and Ameliorates Obesity-Associated Hypertension in Obese ZDF Rats Via Inhibition of Endothelial Autophagy. Cell Physiol Biochem 2017; 43:293-307. [DOI: 10.1159/000480410] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2017] [Accepted: 06/23/2017] [Indexed: 11/19/2022] Open
Abstract
Aims: Obesity is a major risk for hypertension. Endothelial dysfunction contributes to increased peripheral vascular resistance and subsequent hypertension. Autophagy regulates endothelial function, however, whether autophagy is related to hypertension in obesity remains largely unclear. We wished to ascertain: (i) the role of autophagy in obesity-induced hypertension and the underlying mechanisms; (ii) if tetrahydroxystilbene glycoside (TSG) influences endothelial dysfunction and obesity-associated hypertension. Methods: (TSG-treated) male Zucker diabetic fatty (ZDF) rats and cultured human umbilical vein endothelial cells (HUVECs) were used. Blood pressure was measured non-invasively with a tail-cuff system. Westernblotting was performed to determine the expression of autophagy-associated proteins. Autophagy flux was assessed by transfection HUVECs with the Ad-mGFP–RFP–LC3. Results: Compared with their lean counterparts, obese ZDF rats exhibited hypertension and endothelial dysfunction, along with impaired Akt/mTOR signaling and upregulated expression of autophagy-associated proteins beclin1, microtubule-associated protein 1 light chain 3 II/I, autophagy protein (ATG)5 and ATG7. Two-week TSG administration restored blood pressure and endothelial function, reactivated Akt/mTOR pathway and decreased endothelial autophagy in ZDF rats. Rapamycin pretreatment blocked the hypotensive effect of TSG in ZDF rats. Suppression of Akt/mTOR expression with siRNA significantly blunted the anti-autophagic effect of TSG in HUVECs as evidenced by abnormal autophagic flux and increased expression of autophagy-associated proteins. Conclusion: Endothelial dysfunction in ZDF rats is partially attributable to excessive autophagy. TSG improves endothelial function and exerts hypotensive effects via regulation of endothelial autophagy.
Collapse
|
48
|
Jiang YQ, Guo QM, Xu XP, Liang JC, He YY, An SH, Su F, Li CY, Huang CX. [Preparation of chaperone-antigen peptide vaccine derived from human gastric cancer stem cells and its immune function]. Zhonghua Zhong Liu Za Zhi 2017; 39:109-114. [PMID: 28219205 DOI: 10.3760/cma.j.issn.0253-3766.2017.02.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the method of extracting chaperone antigen peptide complexes from gastric cancer stem cells and its immune function. Methods: Gastric cancer stem cells and gastric cancer cells were screened by low temperature ultrasonic lysis. After salting out and dialysis, the lysate supernatant was processed with SDS-PAGE to analyze the expression of chaperone antigen peptide complexes, and then was separated and purified with CNBr-activated SepharoseTM 4B. Reverse high pressure liquid chromatography (HPLC), SDS-PAGE and Western blotting were used to analyze the purity and nature of the acquired albumen. Lymphocyte proliferation assay and lymphocytotoxicity assay were used to ditermine the immunological activity of the chaperone-antigen peptide complexes. Results: The chaperone antigen peptide complexes of gastric cancer stem cells were prepared and identified successfully, of which the main components were the antigen peptides of HSP60, HSP70, HSP90 and HSP110. 0.75 μg and 1.00 μg HSP70-antigen peptide and 1.00 μg HSP90-antigen peptide activated lymphocytes significantly. Their A(490) values were 0.26±0.03, 0.45±0.05 and 0.32±0.04, respectively, while the corresponding doses of HSP60-antigen peptide and HSP110-antigen peptide did not activate lymphocytes. The killing rates of 1.00 μg HSP70-antigen peptide and 1.00 μg HSP70 were (45.0±2.0)% and (16.0±2.0)%, respectively, showing a significant difference (P=0.012). Similarly, the killing rates of 1.00 μg HSP90-antigen peptide and 1.00 μg HSP90 were (36.0±5.0)% and (13.0±4.0)%, respectively, also showing a significant difference (P=0.048). Conclusions: The amount of chaperone antigen peptide complexes in gastric cancer cells is extremely low, but it is obviously increased in gastric cancer stem cells. After purification, the chaperone antigen peptide complexes with high purity can be prepared. The extracted chaperone antigen peptide complexes have stronger immunogenicity, and can be used to make tumor vaccine in vitro, which may have a good application value in the targeted therapy of gastric cancer.
Collapse
Affiliation(s)
- Y Q Jiang
- Department of Radiotherapy, the First People's Hospital of Xiaoshan, Hangzhou 311201, China
| | - Q M Guo
- Department of Radiotherapy, the First People's Hospital of Xiaoshan, Hangzhou 311201, China
| | - X P Xu
- Department of Radiotherapy, the First People's Hospital of Xiaoshan, Hangzhou 311201, China
| | - J C Liang
- Department of Radiotherapy, the First People's Hospital of Xiaoshan, Hangzhou 311201, China
| | - Y Y He
- Department of Radiotherapy, the First People's Hospital of Xiaoshan, Hangzhou 311201, China
| | - S H An
- Department of Radiotherapy, the First People's Hospital of Xiaoshan, Hangzhou 311201, China
| | - F Su
- Department of Radiotherapy, the First People's Hospital of Xiaoshan, Hangzhou 311201, China
| | - C Y Li
- Department of Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, China
| | - C X Huang
- Department of Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou 310015, China
| |
Collapse
|
49
|
Dong Q, Xing W, Su F, Gao F, Wang S, Zhang H. Abstract 208: Excessive Autophagy Contributes to Microvascular Endothelial Dysfunction in Prehypertensive Spontaneously Hypertensive Rats. Circ Res 2017. [DOI: 10.1161/res.121.suppl_1.208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Autophagy exists in vascular endothelial cells, however, the exact role of autophagy in hypertensive-associated vascular endothelial dysfunction remains largely elusive. We assessed the hypothesis that autophagy is one of the mechanisms of endothelial dysfunction in normotensive spontaneously hypertensive rats (SHRs). Age-matched male SHRs and Wistar Kyoto rats (WKY) aged 4 weeks (young) and 12 weeks (adult) were randomized into 2 groups and treated daily for 2 weeks by a) gavage with vehicle alone (normal saline) or b) intraperitoneally injection of rapamycin (1 mg/kg/day), and the vascular function of their isolated aorta and mesenteric artery was assessed
in vitro
. Furthermore, human umbilical vein endothelial cells (HUVECs) were incubated serum-starved for 6 h to induce excessive cell autophagy, and then incubated with DMEM containing 10% FBS and a) treated with 10 nmol/L insulin-like growth factor 1 (IGF-1) for 12 h, b) treated with 100 nmol/L Rapamycin for 1 h for 37°C. Compared with WKY, young and adult SHRs showed endothelial dysfunction of the aorta and mesenteric artery, along with decreased phosphorylated (p)-Akt, p-mTOR, and autophagic marker protein p62 and increased LC3 II/I in microvascular but not aortic tissues. Treatment of young SHRs with the mTOR inhibitor rapamycin aggravated the endothelial autophagy and subsequent impaired endothelial function. Moreover, IGF-1 significantly activated Akt/mTOR signaling in HUVECs and reduced autophagic levels, while rapamycin inhibited p-mTOR and increased autophagic levels. In conclusion, mesenteric endothelial dysfunction in prehypertensive SHRs is at least partly attributable to excessive autophagy in vascular tissues, and is likely mediated by the underactive Akt/mTOR signaling pathway; however, autophagy appears not to be responsible for the macrovascular endothelial dysfunction.
Collapse
Affiliation(s)
| | | | - Feifei Su
- Fourth Military Med Univ, Xian, China
| | - Feng Gao
- Fourth Military Med Univ, Xian, China
| | | | | |
Collapse
|
50
|
Campone M, Marschner N, Villanueva C, Sonke G, Alba E, Jakobsen E, Su F, He W, Germa C, André F. First-line ribociclib + letrozole in HR+, HER2– ABC: Efficacy by baseline tumor markers. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx137] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|